Differing Prevalence and Correlates of Metabolic Syndromes Between
Chlorpromazine and Clozapine: A 10-year Retrospective Study of a Male
Chinese Cohort

Mengjuan      Xing; Jialing      Sheng; Mengxin      Cui; Yousong      Su; Chengfang      Zhang; Xi      Chen; Yu      Fang; Donghong      Cui; Zezhi      Li

doi:10.2174/1570159X20666220302153123

Abstract

Background: Antipsychotics are known to be associated with metabolic syndromes (MetS). Chlorpromazine (CPZ) and Clozapine (CLZ) are currently the most commonly used antipsychotics in low-income districts of China. However, potential differences in the long-term effects of CPZ and CLZ on MetS in schizophrenia inpatients are not well understood. Here, we aimed to identify any MetS profile differences between long-term schizophrenia patients who were prescribed either CPZ or CLZ at a primary psychiatric hospital.

Methods: We recruited a total of 204 male schizophrenia patients who received either CPZ or CLZ. We measured their weight, height, body mass index (BMI), waist circumference (WC), diastolic blood pressure (DBP), and systolic blood pressure (SBP), as well as their biochemical indicators, including fasting blood glucose (FBS), triglycerides (TG), cholesterol (TC), high-density lipoprotein cholesterol (HDL-c) and low-density lipoprotein cholesterol (LDL-c).

Results: The MetS prevalence in the CPZ and CLZ groups was 31% and 37.5%, respectively. The CLZ group had significantly higher DBP levels and a higher incidence of dyslipidemia (HDL-c) but lower HDL-c and TC levels than the CPZ group. We also determined that smoking history, BMI, and duration of hospitalisation were risk factors for the development of MetS. Moreover, we found that CPZ and CLZ were correlated with the same risk for developing MetS and that BMI was a vital risk factor of MetS for both the CPZ and CLZ groups.

Conclusion: Long-term CPZ and CLZ prescriptions were associated with similar profiles for developing MetS of schizophrenia patients.

Keywords: Schizophrenia, metabolic syndrome, antipsychotics, dyslipidemia, diabetes, retrospective cohort study.

« Previous Next »

Graphical Abstract

[1] 
Thornicroft, G. Premature death among people with mental illness. BMJ,  2013, 346, f2969.
[http://dx.doi.org/10.1136/bmj.f2969] [PMID:  23674141] 
[2] 
Laursen, T.M.; Nordentoft, M.; Mortensen, P.B. Excess early mortality in schizophrenia. Annu. Rev. Clin. Psychol.,  2014, 10, 425-448.
[http://dx.doi.org/10.1146/annurev-clinpsy-032813-153657] [PMID:  24313570] 
[3] 
Correll, C.U.; Solmi, M.; Veronese, N.; Bortolato, B.; Rosson, S.; Santonastaso, P.; Thapa-Chhetri, N.; Fornaro, M.; Gallicchio, D.; Collantoni, E.; Pigato, G.; Favaro, A.; Monaco, F.; Kohler, C.; Vancampfort, D.; Ward, P.B.; Gaughran, F.; Carvalho, A.F.; Stubbs, B. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry,  2017, 16(2), 163-180.
[http://dx.doi.org/10.1002/wps.20420] [PMID:  28498599] 
[4] 
Tune, J.D.; Goodwill, A.G.; Sassoon, D.J.; Mather, K.J. Cardiovascular consequences of metabolic syndrome. Transl. Res.,  2017, 183, 57-70.
[http://dx.doi.org/10.1016/j.trsl.2017.01.001] [PMID:  28130064] 
[5] 
Mottillo, S.; Filion, K.B.; Genest, J.; Joseph, L.; Pilote, L.; Poirier, P.; Rinfret, S.; Schiffrin, E.L.; Eisenberg, M.J. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J. Am. Coll. Cardiol.,  2010, 56(14), 1113-1132.
[http://dx.doi.org/10.1016/j.jacc.2010.05.034] [PMID:  20863953] 
[6] 
Anderson, P.J.; Critchley, J.A.; Chan, J.C.; Cockram, C.S.; Lee, Z.S.; Thomas, G.N.; Tomlinson, B. 
            Factor analysis of the metabolic syndrome: obesity 
            vs
             insulin resistance as the central abnormality.
           Int. J. Obes. Relat. Metab. Disord.,  2001, 25(12), 1782-1788.
[http://dx.doi.org/10.1038/sj.ijo.0801837] [PMID:  11781758] 
[7] 
Hanley, A.J.; Karter, A.J.; Festa, A.; D’Agostino, R., Jr; Wagenknecht, L.E.; Savage, P.; Tracy, R.P.; Saad, M.F.; Haffner, S. Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis Study. Diabetes,  2002, 51(8), 2642-2647.
[http://dx.doi.org/10.2337/diabetes.51.8.2642] [PMID:  12145182] 
[8] 
Ellingrod, V.L.; Miller, D.D.; Taylor, S.F.; Moline, J.; Holman, T.; Kerr, J. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr. Res.,  2008, 98(1-3), 47-54.
[http://dx.doi.org/10.1016/j.schres.2007.09.030] [PMID:  17976958] 
[9] 
Malan-Müller, S.; Kilian, S.; van den Heuvel, L.L.; Bardien, S.; Asmal, L.; Warnich, L.; Emsley, R.A.; Hemmings, S.M.; Seedat, S. A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia. Schizophr. Res.,  2016, 170(1), 1-17.
[http://dx.doi.org/10.1016/j.schres.2015.11.011] [PMID:  26621002] 
[10] 
Burghardt, K.J.; Goodrich, J.M.; Lines, B.N.; Ellingrod, V.L. The Influence of Metabolic Syndrome and Sex on the DNA Methylome in Schizophrenia. Int. J. Genomics,  2018, 2018, 8076397.
[http://dx.doi.org/10.1155/2018/8076397] [PMID:  29850476] 
[11] 
Zhou, Y.; Song, X.; Guo, Y.; Lang, X.; Li, Z.; Zhang, X.Y. Sex differences in metabolic disorder patterns of first-episode drug-naive patients with schizophrenia. Psychoneuroendocrinology,  2021, 124, 105061.
[http://dx.doi.org/10.1016/j.psyneuen.2020.105061] [PMID:  33291004] 
[12] 
Lin, Y.Z.; Peng, Y.M.; He, S.; Xu, J.J.; Shi, Y.; Su, Y.S.; Zhu, C.Z.; Zhang, X.Y.; Zhou, R.B.; Cui, D.H. Serum IL-1ra, a novel
biomarker predicting olanzapine-induced hypercholesterolemia and
hyperleptinemia in schizophrenia. Prog Neuropsychopharmacol
Biol Psychiatry,  2018, 84(Pt A), 71-78.
[http://dx.doi.org/10.1016/j.pnpbp.2018.01.020] [PMID: 29410009] 
[13] 
Stubbs, B.; Koyanagi, A.; Schuch, F.; Firth, J.; Rosenbaum, S.; Gaughran, F.; Mugisha, J.; Vancampfort, D. Physical activity levels and psychosis: A mediation analysis of factors influencing physical activity target achievement among 204 186 people across 46 low- and middle-income countries. Schizophr. Bull.,  2017, 43(3), 536-545.
[http://dx.doi.org/10.1093/schbul/sbw111] [PMID:  27562855] 
[14] 
Mitchell, A.J.; Vancampfort, D.; Sweers, K.; van Winkel, R.; Yu, W.; De Hert, M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. Schizophr. Bull.,  2013, 39(2), 306-318.
[http://dx.doi.org/10.1093/schbul/sbr148] [PMID:  22207632] 
[15] 
Xu, J.; Jiao, Y.; Xing, M.; Lin, Y.; Su, Y.; Ding, W.; Zhu, C.; Peng, Y.; Qi, D.; Cui, D. Increased plasma leptin as a novel predictor for psychopathological depressive symptoms in chronic schizophrenia. Gen. Psychiatr.,  2018, 31(3), e100018.
[http://dx.doi.org/10.1136/gpsych-2018-100018] [PMID:  30815631] 
[16] 
Rojo, L.E.; Gaspar, P.A.; Silva, H.; Risco, L.; Arena, P.; Cubillos-Robles, K.; Jara, B. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. Pharmacol. Res.,  2015, 101, 74-85.
[http://dx.doi.org/10.1016/j.phrs.2015.07.022] [PMID:  26218604] 
[17] 
Liu, M.Z.; He, H.Y.; Luo, J.Q.; He, F.Z.; Chen, Z.R.; Liu, Y.P.; Xiang, D.X.; Zhou, H.H.; Zhang, W. Drug-induced hyperglycaemia and diabetes: pharmacogenomics perspectives. Arch. Pharm. Res.,  2018, 41(7), 725-736.
[http://dx.doi.org/10.1007/s12272-018-1039-x] [PMID:  29858981] 
[18] 
De Hert, M.; Schreurs, V.; Sweers, K.; Van Eyck, D.; Hanssens, L.; Sinko, S.; Wampers, M.; Scheen, A.; Peuskens, J.; van Winkel, R. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr. Res.,  2008, 101(1-3), 295-303.
[http://dx.doi.org/10.1016/j.schres.2008.01.028] [PMID:  18299188] 
[19] 
Saddichha, S.; Manjunatha, N.; Ameen, S.; Akhtar, S. Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study. Schizophr. Res.,  2008, 101(1-3), 266-272.
[http://dx.doi.org/10.1016/j.schres.2008.01.004] [PMID:  18262771] 
[20] 
Ijaz, S.; Bolea, B.; Davies, S.; Savović, J.; Richards, A.; Sullivan, S.; Moran, P. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews. BMC Psychiatry,  2018, 18(1), 275.
[http://dx.doi.org/10.1186/s12888-018-1848-y] [PMID:  30176844] 
[21] 
Hirsch, L.; Yang, J.; Bresee, L.; Jette, N.; Patten, S.; Pringsheim, T. Second-generation antipsychotics and metabolic side effects: A systematic review of population-based studies. Drug Saf.,  2017, 40(9), 771-781.
[http://dx.doi.org/10.1007/s40264-017-0543-0] [PMID:  28585153] 
[22] 
Lee, J.S.; Kwon, J.S.; Kim, D.; Kim, S.W.; Kim, J.J.; Kim, J.H.; Nam, H.J.; Ryu, S.; Park, I.H.; An, S.K.; Oh, H.S.; Won, S.; Lee, K.; Lee, K.Y.; Lee, S.H.; Lee, Y.S.; Yi, J.S.; Hong, K.S.; Joo, Y.H. Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study. Psychiatry Investig.,  2017, 14(1), 44-50.
[http://dx.doi.org/10.4306/pi.2017.14.1.44] [PMID:  28096874] 
[23] 
Said, M.A.; Sulaiman, A.H.; Habil, M.H.; Das, S.; Bakar, A.K.; Yusoff, R.M.; Loo, T.H.; Bakar, S.A. Metabolic syndrome and cardiovascular
risk among patients with schizophrenia receiving antipsychotics
in Malaysia. Singapore Med. J.,  2012, 53(12), 801-807.
[PMID:  23268153] 
[24] 
De Hert, M.; Cohen, D.; Bobes, J.; Cetkovich-Bakmas, M.; Leucht, S.; Ndetei, D.M.; Newcomer, J.W.; Uwakwe, R.; Asai, I.; Möller, H.J.; Gautam, S.; Detraux, J.; Correll, C.U. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry,  2011, 10(2), 138-151.
[http://dx.doi.org/10.1002/j.2051-5545.2011.tb00036.x] [PMID:  21633691] 
[25] 
Allison, D.B.; Mentore, J.L.; Heo, M.; Chandler, L.P.; Cappelleri, J.C.; Infante, M.C.; Weiden, P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry,  1999, 156(11), 1686-1696.
[http://dx.doi.org/10.1176/ajp.156.11.1686] [PMID:  10553730] 
[26] 
Heng, D.; Ma, S.; Lee, J.J.; Tai, B.C.; Mak, K.H.; Hughes, K.; Chew, S.K.; Chia, K.S.; Tan, C.E.; Tai, E.S. Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis,  2006, 186(2), 367-373.
[http://dx.doi.org/10.1016/j.atherosclerosis.2005.07.020] [PMID:  16112123] 
[27] 
WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet,  2004, 363(9403), 157-163.
[http://dx.doi.org/10.1016/S0140-6736(03)15268-3] [PMID:  14726171] 
[28] 
Dekker, J.M.; Girman, C.; Rhodes, T.; Nijpels, G.; Stehouwer, C.D.; Bouter, L.M.; Heine, R.J. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation,  2005, 112(5), 666-673.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.104.516948] [PMID:  16061755] 
[29] 
Beltrán-Sánchez, H.; Harhay, M.O.; Harhay, M.M.; McElligott, S. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010. J. Am. Coll. Cardiol.,  2013, 62(8), 697-703.
[http://dx.doi.org/10.1016/j.jacc.2013.05.064] [PMID:  23810877] 
[30] 
Huang, M-C.; Lu, M-L.; Tsai, C-J.; Chen, P-Y.; Chiu, C-C.; Jian, D-L.; Lin, K-M.; Chen, C-H. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr. Scand.,  2009, 120(4), 274-280.
[http://dx.doi.org/10.1111/j.1600-0447.2009.01401.x] [PMID:  19426161] 
[31] 
Sugawara, N.; Yasui-Furukori, N.; Sato, Y.; Kishida, I.; Yamashita, H.; Saito, M.; Furukori, H.; Nakagami, T.; Hatakeyama, M.; Kaneko, S. Comparison of prevalence of metabolic syndrome in hospital and community-based Japanese patients with schizophrenia. Ann. Gen. Psychiatry,  2011, 10, 21.
[http://dx.doi.org/10.1186/1744-859X-10-21] [PMID:  21910863] 
[32] 
Seow, L.S.; Chong, S.A.; Wang, P.; Shafie, S.; Ong, H.L.; Subramaniam, M. Metabolic syndrome and cardiovascular risk among institutionalized patients with schizophrenia receiving long term tertiary care. Compr. Psychiatry,  2017, 74, 196-203.
[http://dx.doi.org/10.1016/j.comppsych.2017.01.017] [PMID:  28214752] 
[33] 
Suvisaari, J.M.; Saarni, S.I.; Perälä, J.; Suvisaari, J.V.; Härkänen, T.; Lönnqvist, J.; Reunanen, A. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J. Clin. Psychiatry,  2007, 68(7), 1045-1055.
[http://dx.doi.org/10.4088/JCP.v68n0711] [PMID:  17685741] 
[34] 
Lamberti, J.S.; Olson, D.; Crilly, J.F.; Olivares, T.; Williams, G.C.; Tu, X.; Tang, W.; Wiener, K.; Dvorin, S.; Dietz, M.B. Prevalence of the metabolic syndrome among patients receiving clozapine. Am. J. Psychiatry,  2006, 163(7), 1273-1276.
[http://dx.doi.org/10.1176/ajp.2006.163.7.1273] [PMID:  16816234] 
[35] 
Wirshing, D.A.; Wirshing, W.C.; Kysar, L.; Berisford, M.A.; Goldstein, D.; Pashdag, J.; Mintz, J.; Marder, S.R. Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psychiatry,  1999, 60(6), 358-363.
[http://dx.doi.org/10.4088/JCP.v60n0602] [PMID:  10401912] 
[36] 
Lameh, J.; Burstein, E.S.; Taylor, E.; Weiner, D.M.; Vanover, K.E.; Bonhaus, D.W. Pharmacology of N-desmethylclozapine. Pharmacol. Ther.,  2007, 115(2), 223-231.
[http://dx.doi.org/10.1016/j.pharmthera.2007.05.004] [PMID:  17583355] 
[37] 
Shan, L.; Swaab, D.F. Changes in histaminergic system in neuropsychiatric disorders and the potential treatment consequences. Curr. Neuropharmacol.,  2022, 20(2), 403-411.
[http://dx.doi.org/10.2174/1570159X19666210909144930] [PMID:  34521328] 
[38] 
Reynolds, G.P.; Templeman, L.A.; Zhang, Z.J. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry,  2005, 29(6), 1021-1028.
[http://dx.doi.org/10.1016/j.pnpbp.2005.03.019] [PMID:  15953671] 
[39] 
Lu, M.L.; Lane, H.Y.; Lin, S.K.; Chen, K.P.; Chang, W.H. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J. Clin. Psychiatry,  2004, 65(6), 766-771.
[http://dx.doi.org/10.4088/JCP.v65n0607] [PMID:  15291653] 
[40] 
Procyshyn, R.M.; Wasan, K.M.; Thornton, A.E.; Barr, A.M.; Chen, E.Y.; Pomarol-Clotet, E.; Stip, E.; Williams, R.; Macewan, G.W.; Birmingham, C.L.; Honer, W.G. Changes in serum lipids, independent
of weight, are associated with changes in symptoms during
long-term clozapine treatment. J. Psychiatry Neurosci.,  2007, 32(5), 331-338.
[PMID:  17823649] 
[41] 
Contreras-Shannon, V.; Heart, D.L.; Paredes, R.M.; Navaira, E.; Catano, G.; Maffi, S.K.; Walss-Bass, C. Clozapine-induced mitochondria alterations and inflammation in brain and insulin-responsive cells. PLoS One,  2013, 8(3), e59012.
[http://dx.doi.org/10.1371/journal.pone.0059012] [PMID:  23527073] 
[42] 
Zhang, C.; Zhang, Y.; Cai, J.; Chen, M.; Song, L. Complement 3 and metabolic syndrome induced by clozapine: a cross-sectional study and retrospective cohort analysis. Pharmacogenomics J.,  2017, 17(1), 92-97.
[http://dx.doi.org/10.1038/tpj.2015.68] [PMID:  26503818] 
[43] 
Liu, H.; Yu, R.; Gao, Y.; Li, X.; Guan, X.; Thomas, K.; Xiu, M.; Zhang, X. Antioxidant enzymes and weight gain in drug-naive first episode schizophrenia patients treated with risperidone for 12 weeks: a prospective longitudinal study. Curr. Neuropharmacol., 2021. Online ahead of print
[http://dx.doi.org/10.2174/1570159X19666210920090547] [PMID:  34544343] 
[44] 
Basile, V.S.; Masellis, M.; McIntyre, R.S.; Meltzer, H.Y.; Lieberman, J.A.; Kennedy, J.L. Genetic dissection of atypical antipsychotic-
induced weight gain: novel preliminary data on the pharmacogenetic
puzzle. J. Clin. Psychiatry,  2001, 62(Suppl. 23), 45-66.
[PMID:  11603885] 
[45] 
Trichard, C.; Paillère-Martinot, M.L.; Attar-Levy, D.; Recassens, C.; Monnet, F.; Martinot, J.L. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am. J. Psychiatry,  1998, 155(4), 505-508.
[http://dx.doi.org/10.1176/ajp.155.4.505] [PMID:  9545996] 
[46] 
Inoue, A.; Nakata, Y. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy. Jpn. J. Pharmacol.,  2001, 86(4), 376-380.
[http://dx.doi.org/10.1254/jjp.86.376] [PMID:  11569610] 
[47] 
Matsushita, M.; Egashira, N.; Harada, S.; Okuno, R.; Mishima, K.; Iwasaki, K.; Nishimura, R.; Fujiwara, M. 
            Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior 
            via
             5-HT1A receptor in mice: implications for obsessive-compulsive disorder.
           J. Pharmacol. Sci.,  2005, 99(2), 154-159.
[http://dx.doi.org/10.1254/jphs.FP0050144] [PMID:  16210777] 
[48] 
Kato, M.M.; Goodnick, P.J. Antipsychotic medication: effects on regulation of glucose and lipids. Expert Opin. Pharmacother.,  2001, 2(10), 1571-1582.
[http://dx.doi.org/10.1517/14656566.2.10.1571] [PMID:  11825300] 
[49] 
Amamoto, T.; Kumai, T.; Nakaya, S.; Matsumoto, N.; Tsuzuki, Y.; Kobayashi, S. The elucidation of the mechanism of weight gain and glucose tolerance abnormalities induced by chlorpromazine. J. Pharmacol. Sci.,  2006, 102(2), 213-219.
[http://dx.doi.org/10.1254/jphs.FP0060673] [PMID:  17031068] 
[50] 
De Hert, M.A.; van Winkel, R.; Van Eyck, D.; Hanssens, L.; Wampers, M.; Scheen, A.; Peuskens, J. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr. Res.,  2006, 83(1), 87-93.
[http://dx.doi.org/10.1016/j.schres.2005.12.855] [PMID:  16481149] 
[51] 
Yoca, G.; Yağcıoğlu, A.E.; Eni, N.; Karahan, S.; Türkoğlu, I.; Yıldız, E.A.; Mercanlıgil, S.M.; Yazici, M.K. A follow-up study of metabolic syndrome in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci.,  2020, 270(5), 611-618.
[http://dx.doi.org/10.1007/s00406-019-01016-x] [PMID:  31030256] 
[52] 
Shi, L.; Ascher-Svanum, H.; Chiang, Y.J.; Zhao, Y.; Fonseca, V.; Winstead, D. Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration. BMC Psychiatry,  2009, 9, 80.
[http://dx.doi.org/10.1186/1471-244X-9-80] [PMID:  20021664] 
[53] 
Wing, R.R.; Blair, E.; Marcus, M.; Epstein, L.H.; Harvey, J. Year-long weight loss treatment for obese patients with type II diabetes: does including an intermittent very-low-calorie diet improve outcome? Am. J. Med.,  1994, 97(4), 354-362.
[http://dx.doi.org/10.1016/0002-9343(94)90302-6] [PMID:  7942937] 
[54] 
Lindström, J.; Louheranta, A.; Mannelin, M.; Rastas, M.; Salminen, V.; Eriksson, J.; Uusitupa, M.; Tuomilehto, J. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care,  2003, 26(12), 3230-3236.
[http://dx.doi.org/10.2337/diacare.26.12.3230] [PMID:  14633807] 
[55] 
Liu, H.X.; Liu, H.; Jiang, S.L.; Su, L.; Lu, Y.; Chen, Z.L.; Li, X.J.; Li, X.R.; Wang, X.M.; Xiu, M.H.; Zhang, X.Y. Sex-specific association between antioxidant defense system and therapeutic response to risperidone in schizophrenia: a prospective longitudinal study. Curr. Neuropharmacol., 2021. Online ahead of print
[http://dx.doi.org/10.2174/1570159X19666211111123918] [PMID:  34766896] 
[56] 
Zhu, M.; Liu, Z.; Guo, Y.; Sultana, M.S.; Wu, K.; Lang, X.; Lv, Q.; Huang, X.; Yi, Z.; Li, Z. Sex difference in the interrelationship between TNF-α and oxidative stress status in first-episode drug-naïve schizophrenia. J. Neuroinflammation,  2021, 18(1), 202.
[http://dx.doi.org/10.1186/s12974-021-02261-5] [PMID:  34526062] 
[57] 
Rezaei, O.; Khodaie-Ardakani, M.R.; Mandegar, M.H.; Dogmehchi, E.; Goodarzynejad, H. Prevalence of metabolic syndrome among an Iranian cohort of inpatients with schizophrenia. Int. J. Psychiatry Med.,  2009, 39(4), 451-462.
[http://dx.doi.org/10.2190/PM.39.4.i] [PMID:  20391865] 
[58] 
Yazici, M.K.; Anil Yağcioğlu, A.E.; Ertuğrul, A.; Eni, N.; Karahan, S.; Karaağaoğlu, E.; Tokgözoğlu, S.L. The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey. Eur. Arch. Psychiatry Clin. Neurosci.,  2011, 261(1), 69-78.
[http://dx.doi.org/10.1007/s00406-010-0118-x] [PMID:  20517698] 
[59] 
De Hert, M.; van Eyck, D.; De Nayer, A. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int. Clin. Psychopharmacol.,  2006, 21(Suppl. 2), S11-S15.
[http://dx.doi.org/10.1097/01.yic.0000201496.23259.85] [PMID:  16601508] 

Rights & Permissions Print Cite

Article Metrics

18

1

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1570159X20666220302153123	Print ISSN 1570-159X
Publisher Name Bentham Science Publisher	Online ISSN 1875-6190

Current Neuropharmacology

Differing Prevalence and Correlates of Metabolic Syndromes Between Chlorpromazine and Clozapine: A 10-year Retrospective Study of a Male Chinese Cohort

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Abstract